Healthcare technology firm Covidien has appointed Mark Trudeau as president of its pharmaceuticals segment and a senior vice president of the company, effective February 1.
Trudeau currently serves as president and CEO of Bayer HealthCare and also as president and CEO of Bayer HealthCare Pharmaceuticals U.S. Region. Prior to joining Bayer, Trudeau was senior vice president and general manager of the Bristol-Myers Squibb Immunology Division.
Trudeau succeeds Matthew Harbaugh, chief financial officer of the pharmaceuticals segment, who has served as interim president since November 2010, when former pharmaceuticals president Timothy Wright resigned. Harbaugh will continue as chief financial officer of the business.
On December 15, 2011, Covidien unveiled plans to spin off its pharmaceuticals segment into a standalone public company. Covidien anticipates that the transaction could take up to 18 months to complete. Covidien's pharmaceuticals unit supplies generators for the production of the medical isotope technetium-99.
